Valuation: CSL Limited

Market Cap 40.94B 35.81B 33.03B 30.5B 57.88B 3,904B 58.85B 395B 155B 1,923B 154B 150B 6,612B P/E 2026 *
-46x
P/E 2027 * 28.5x
Enterprise Value 49.79B 43.55B 40.17B 37.1B 70.39B 4,748B 71.58B 480B 188B 2,339B 187B 183B 8,041B EV / Sales 2026 *
3.23x
EV / Sales 2027 * 3.13x
Free-Float
99.3%
Yield 2026 *
3.34%
Yield 2027 * 3.42%
1 day-1.55%
1 week+5.49%
Current month+7.73%
1 month+20.39%
3 months-12.58%
6 months-26.16%
Current year-24.97%
1 week 21.31
Extreme 21.31
22.54
1 month 18.41
Extreme 18.41
22.54
Current year 16.01
Extreme 16.01
33.53
1 year 16.01
Extreme 16.01
44.86
3 years 16.01
Extreme 16.01
54.5
5 years 16.01
Extreme 16.01
58.62
10 years 16.01
Extreme 16.01
58.99
Manager TitleAgeSince
Chief Executive Officer 63 10/02/2026
Director of Finance/CFO 52 06/10/2025
Chief Operating Officer - 30/04/2025
Director TitleAgeSince
Director/Board Member 72 16/10/2018
Director/Board Member 70 01/02/2011
Director/Board Member 71 08/12/2019
Change 5-day change 1-year change 3-year change Capi.($)
-1.55%+5.49% - - 40.94B
-0.51%+1.57%+18.72%-5.52% 67.61B
-5.16%-8.63%+37.37%+202.27% 51.6B
+5.28%+39.50%+39.50%+39.50% 43B
+0.12%-7.85%+47.16%-29.27% 29.4B
-10.83%-14.41%+99.15%-44.54% 27.09B
-1.53%-0.13%+65.92%+88.58% 23.32B
+3.88%+2.16%+11.78%+201.51% 19.89B
-1.59%-1.63%+61.04%+130.75% 16.91B
-4.75%+11.27%+85.63%+394.76% 16.84B
Average -1.66%-1.87%+51.81%+108.67% 32.85B
Weighted average by Cap. -1.46%-2.55%+44.68%+83.29%

Financials

2026 *2027 *
Net sales 15.39B 13.46B 12.42B 11.47B 21.76B 1,468B 22.13B 148B 58.27B 723B 57.79B 56.53B 2,486B 15.64B 13.68B 12.61B 11.65B 22.11B 1,491B 22.48B 151B 59.19B 735B 58.71B 57.43B 2,525B
Net income -894M -782M -721M -666M -1.26B -85.22B -1.28B -8.61B -3.38B -41.98B -3.36B -3.28B -144B 1.18B 1.03B 955M 882M 1.67B 113B 1.7B 11.41B 4.48B 55.59B 4.44B 4.35B 191B
Net Debt 8.85B 7.74B 7.14B 6.59B 12.51B 844B 12.72B 85.31B 33.5B 416B 33.23B 32.5B 1,429B 8.07B 7.06B 6.51B 6.01B 11.41B 770B 11.6B 77.8B 30.55B 379B 30.3B 29.64B 1,304B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,904
Date Price Change Volume
10/07/26 US$21.61 -1.55% 437,967
09/07/26 US$21.95 +1.57% 247,348
08/07/26 US$21.61 -0.32% 489,337
07/07/26 US$21.68 -0.50% 796,933
06/07/26 US$21.79 +6.37% 482,137
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
85.48USD
Average target price
96.64USD
Spread / Average Target
+13.06%

Quarterly revenue - Rate of surprise